August 21, 2018
BERGEN , Norway, 21 Aug, 2018 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, announces its results for the second quarter and first half 2018. A presentation of the...
Source URL: https://www.prnewswire.com:443/news-releases/bergenbio-asa-results-for-the-second-quarter-and-first-half-2018-300699959.html
|
